Quemliclustat

Phase 3

Arcus Biosciences, Inc. (RCUS)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jan '27

RCUSPhase 2$3.1B

Quemliclustat Phase 2 Est. Readout

Quemliclustat• Gastrointestinal Tract Malignancies332

Jan 2027~ConfirmedSTALE

CT.gov

00%

Jan '27

RCUSPhase 3$3.1B

Quemliclustat Phase 3 Est. Readout

Quemliclustat• Gastrointestinal Tract Malignancies610

Jan 2027~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Gastrointestinal Tract Malignancies

View Full Landscape

Drug Information

Target Indication

Gastrointestinal Tract Malignancies

Clinical Trial

NCT05329766

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

RCUS

Arcus Biosciences, Inc.

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

DomvanalimabPhase 3

Advanced Upper Gastrointestinal Tract Adenocarcinoma

CasdatifanPhase 3

Metastatic Clear Cell Renal Cell Carcinoma

ZimberelimabPhase 3

Non Small Cell Lung Cancer

AB680Phase 2

Metastatic Colorectal Cancer

EtrumadenantPhase 2

Prostatic Neoplasms, Castration-Resistant

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts